1. ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3Kδ INHIBITOR, FOR THE TREATMENT OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES (CITADEL‐101). (June 2017) Authors: Caimi, P.; Ramchandren, R.; Phillips, T.J.; Wertheim, M.S.; Gutierrez, M.E.; Edenfield, W.J.; Akard, L.P.; Call, J.A.; Persky, D.O.; DeMarini, D.J.; Zhou, L.; Yeleswaram, S.; Forero‐Torres, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 268 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). (12th June 2019) Authors: Tam, C.S.; Wang, M.; Simpson, D.; Opat, S.; Cull, G.; Munoz, J.; Phillips, T.J.; Kim, W.; Atwal, S.; Wei, R.; Huang, J.; Elstrom, R.; Trotman, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗